Fate Therapeutics (FATE) Reports Q2 Loss, Tops Revenue Estimates

Fate Therapeutics (FATE) came out with a quarterly loss of $0.33 per share versus the Zacks Consensus Estimate of a loss of$ 0.47. This compares to loss of $0.54 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of 29.79%. A quarter ago, it was expected that this clinicalstage biotech company that develops stem cell treatments would post a loss of$ 0.47 per share when it actually produced a loss of $0.47, delivering no surprise. O ...